Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by State Street Corp

State Street Corp raised its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 8.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,728,888 shares of the company’s stock after acquiring an additional 137,145 shares during the quarter. State Street Corp owned 3.26% of Stoke Therapeutics worth $21,248,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in STOK. Quest Partners LLC acquired a new stake in Stoke Therapeutics during the second quarter valued at approximately $29,000. Nisa Investment Advisors LLC lifted its position in shares of Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after acquiring an additional 1,038 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Stoke Therapeutics during the 2nd quarter valued at $123,000. Intech Investment Management LLC bought a new stake in shares of Stoke Therapeutics during the 3rd quarter worth $160,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after acquiring an additional 1,994 shares during the last quarter.

Insider Buying and Selling

In other news, General Counsel Jonathan Allan sold 13,666 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $13.61, for a total transaction of $185,994.26. Following the transaction, the general counsel now owns 21,476 shares of the company’s stock, valued at approximately $292,288.36. This represents a 38.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Barry Ticho sold 13,945 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $178,217.10. Following the completion of the transaction, the insider now directly owns 47,332 shares in the company, valued at $604,902.96. The trade was a 22.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 62,849 shares of company stock worth $809,421. Insiders own 11.30% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on STOK. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Leerink Partners initiated coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Stoke Therapeutics currently has an average rating of “Buy” and an average price target of $21.29.

Stoke Therapeutics Stock Down 0.6 %

Stoke Therapeutics stock opened at $11.61 on Tuesday. Stoke Therapeutics, Inc. has a 12 month low of $4.09 and a 12 month high of $17.58. The stock has a market cap of $614.95 million, a P/E ratio of -5.53 and a beta of 0.95. The company’s fifty day simple moving average is $12.48 and its 200-day simple moving average is $13.52.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. On average, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.